New cancer drugs: little extra benefit, higher price
New anticancer drugs reaching the European market in 1995-2000 offer
few or no substantial advantages over existing preparations yet cost
several times as much. Garattini and Bertele' (p 269) outline the
features of the 12 new anticancer drugs approved for marketing and
say that the general population of cancer patients will gain no benefit
from them. It is hoped, however, that some new anticancer drugs, such
as anti-angiogenic agents and resistant revertants, will soon undergo
adequate clinical testing and show benefits over current treatments.
(Credit: RAY TANG/REX)
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
StumbleUpon 
Technorati What's this?
Relevant Article
- Efficacy, safety, and cost of new anticancer drugs
- Silvio Garattini and Vittorio Bertele'
BMJ 2002 325: 269-271.[Extract] [Full Text] [PDF]
This Article
- Respond to this article
- Alert me when this article is cited
- Alert me when responses are posted
- Alert me when a correction is posted
Services
- Email this article to a friend
- Find similar articles in BMJ
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
Related Content
Bookmark with
What's new
Latest blogs
Find BMJ on:
Services
Tools
Online poll
Resources
Rapid responses for this article
There are no rapid responses for this article. Print issues
